NanJing Pharmaceutical Company Limited (600713.SS)
CNY 5.2
(-0.38%)
CNY 5.2
(-0.38%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 577.82 Million CNY | -3.0% |
| 2022 | 595.66 Million CNY | 17.91% |
| 2021 | 505.18 Million CNY | 34.21% |
| 2020 | 376.41 Million CNY | 8.5% |
| 2019 | 346.92 Million CNY | 31.26% |
| 2018 | 264.29 Million CNY | 10.46% |
| 2017 | 239.27 Million CNY | 32.73% |
| 2016 | 180.27 Million CNY | 15.02% |
| 2015 | 156.72 Million CNY | 21.6% |
| 2014 | 128.88 Million CNY | 233.19% |
| 2013 | 38.68 Million CNY | 257.48% |
| 2012 | 10.82 Million CNY | 105.93% |
| 2011 | -182.61 Million CNY | -2048.19% |
| 2010 | 9.37 Million CNY | -79.73% |
| 2009 | 46.24 Million CNY | 52.44% |
| 2008 | 30.33 Million CNY | -35.02% |
| 2007 | 46.67 Million CNY | 151.18% |
| 2006 | 18.58 Million CNY | 1.25% |
| 2005 | 18.35 Million CNY | 664.19% |
| 2004 | 2.4 Million CNY | -88.31% |
| 2003 | 20.53 Million CNY | -27.16% |
| 2002 | 28.19 Million CNY | -23.58% |
| 2001 | 36.89 Million CNY | -23.96% |
| 2000 | 48.52 Million CNY | -34.44% |
| 1999 | 74.01 Million CNY | 24.58% |
| 1998 | 59.41 Million CNY | 55.91% |
| 1997 | 38.1 Million CNY | 26.09% |
| 1996 | 30.22 Million CNY | 75.13% |
| 1995 | 17.25 Million CNY | 26.24% |
| 1994 | 13.67 Million CNY | 65.44% |
| 1993 | 8.26 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 159.08 Million CNY | 15.67% |
| 2024 Q2 | 152.23 Million CNY | -4.3% |
| 2024 Q3 | 130.56 Million CNY | -14.24% |
| 2023 Q2 | 159.48 Million CNY | 6.92% |
| 2023 Q4 | 137.53 Million CNY | 4.46% |
| 2023 FY | 577.82 Million CNY | -3.0% |
| 2023 Q1 | 149.15 Million CNY | 18.92% |
| 2023 Q3 | 131.65 Million CNY | -17.45% |
| 2022 Q1 | 132.55 Million CNY | -16.56% |
| 2022 Q2 | 200.66 Million CNY | 51.38% |
| 2022 Q3 | 137.02 Million CNY | -31.72% |
| 2022 Q4 | 125.42 Million CNY | -8.46% |
| 2022 FY | 595.66 Million CNY | 17.91% |
| 2021 Q1 | 101.95 Million CNY | 8.77% |
| 2021 FY | 505.18 Million CNY | 34.21% |
| 2021 Q2 | 120.4 Million CNY | 18.09% |
| 2021 Q3 | 123.96 Million CNY | 2.96% |
| 2021 Q4 | 158.85 Million CNY | 28.14% |
| 2020 Q4 | 93.73 Million CNY | -14.78% |
| 2020 FY | 376.41 Million CNY | 8.5% |
| 2020 Q1 | 75.95 Million CNY | 44.48% |
| 2020 Q2 | 96.73 Million CNY | 27.35% |
| 2020 Q3 | 109.98 Million CNY | 13.7% |
| 2019 Q1 | 72.19 Million CNY | 8.06% |
| 2019 Q3 | 134.6 Million CNY | 53.76% |
| 2019 FY | 346.92 Million CNY | 31.26% |
| 2019 Q4 | 52.57 Million CNY | -60.94% |
| 2019 Q2 | 87.54 Million CNY | 21.26% |
| 2018 Q2 | 72.52 Million CNY | 12.18% |
| 2018 Q3 | 60.08 Million CNY | -17.16% |
| 2018 FY | 264.29 Million CNY | 10.46% |
| 2018 Q4 | 66.81 Million CNY | 11.2% |
| 2018 Q1 | 64.64 Million CNY | -1.51% |
| 2017 Q3 | 61.26 Million CNY | 16.76% |
| 2017 Q1 | 59.89 Million CNY | 16.32% |
| 2017 Q4 | 65.64 Million CNY | 7.15% |
| 2017 Q2 | 52.46 Million CNY | -12.41% |
| 2017 FY | 239.27 Million CNY | 32.73% |
| 2016 Q3 | 47.37 Million CNY | 48.74% |
| 2016 Q1 | 49.55 Million CNY | 40.74% |
| 2016 FY | 180.27 Million CNY | 15.02% |
| 2016 Q4 | 51.49 Million CNY | 8.7% |
| 2016 Q2 | 31.85 Million CNY | -35.72% |
| 2015 FY | 156.72 Million CNY | 21.6% |
| 2015 Q2 | 32.28 Million CNY | -33.09% |
| 2015 Q4 | 35.2 Million CNY | -14.09% |
| 2015 Q3 | 40.98 Million CNY | 26.93% |
| 2015 Q1 | 48.24 Million CNY | -38.03% |
| 2014 Q3 | 25.22 Million CNY | 63.23% |
| 2014 Q4 | 77.85 Million CNY | 208.59% |
| 2014 FY | 128.88 Million CNY | 233.19% |
| 2014 Q1 | 10.33 Million CNY | -42.89% |
| 2014 Q2 | 15.45 Million CNY | 49.52% |
| 2013 Q4 | 18.1 Million CNY | 336.27% |
| 2013 Q1 | 3.61 Million CNY | -63.17% |
| 2013 FY | 38.68 Million CNY | 257.48% |
| 2013 Q3 | 4.14 Million CNY | -67.63% |
| 2013 Q2 | 12.81 Million CNY | 255.0% |
| 2012 Q1 | -22.96 Million CNY | 87.51% |
| 2012 Q2 | -27.94 Million CNY | -21.68% |
| 2012 Q3 | 51.93 Million CNY | 285.82% |
| 2012 Q4 | 9.8 Million CNY | -81.12% |
| 2012 FY | 10.82 Million CNY | 105.93% |
| 2011 Q4 | -183.84 Million CNY | -25992.25% |
| 2011 Q2 | -4.09 Million CNY | -167.86% |
| 2011 Q1 | 6.02 Million CNY | 125.43% |
| 2011 FY | -182.61 Million CNY | -2048.19% |
| 2011 Q3 | -704.61 Thousand CNY | 82.77% |
| 2010 Q2 | 16.19 Million CNY | 43.74% |
| 2010 Q1 | 11.26 Million CNY | 255.16% |
| 2010 Q4 | -23.69 Million CNY | -522.36% |
| 2010 FY | 9.37 Million CNY | -79.73% |
| 2010 Q3 | 5.61 Million CNY | -65.35% |
| 2009 Q3 | 12.05 Million CNY | -42.0% |
| 2009 FY | 46.24 Million CNY | 52.44% |
| 2009 Q4 | 3.17 Million CNY | -73.68% |
| 2009 Q1 | 10.3 Million CNY | 205.74% |
| 2009 Q2 | 20.77 Million CNY | 101.54% |
| 2008 Q2 | 17.75 Million CNY | 74.33% |
| 2008 FY | 30.33 Million CNY | -35.02% |
| 2008 Q4 | -9.75 Million CNY | -180.26% |
| 2008 Q3 | 12.14 Million CNY | -31.57% |
| 2008 Q1 | 10.18 Million CNY | -12.23% |
| 2007 Q4 | 11.6 Million CNY | -21.84% |
| 2007 Q1 | 7.55 Million CNY | 15.25% |
| 2007 FY | 46.67 Million CNY | 151.18% |
| 2007 Q2 | 12.67 Million CNY | 67.9% |
| 2007 Q3 | 14.84 Million CNY | 17.08% |
| 2006 Q1 | 5.1 Million CNY | -27.84% |
| 2006 FY | 18.58 Million CNY | 1.25% |
| 2006 Q4 | 6.55 Million CNY | 44.15% |
| 2006 Q3 | 4.54 Million CNY | 68.2% |
| 2006 Q2 | 2.7 Million CNY | -47.01% |
| 2005 Q4 | 7.06 Million CNY | 36.38% |
| 2005 Q1 | 5.3 Million CNY | 156.69% |
| 2005 Q2 | 801.99 Thousand CNY | -84.87% |
| 2005 Q3 | 5.18 Million CNY | 546.19% |
| 2005 FY | 18.35 Million CNY | 664.19% |
| 2004 Q2 | 6.46 Million CNY | 29.45% |
| 2004 FY | 2.4 Million CNY | -88.31% |
| 2004 Q1 | 4.99 Million CNY | 6706.18% |
| 2004 Q3 | 290.91 Thousand CNY | -95.5% |
| 2004 Q4 | -9.35 Million CNY | -3315.1% |
| 2003 FY | 20.53 Million CNY | -27.16% |
| 2003 Q4 | -75.63 Thousand CNY | -101.84% |
| 2003 Q1 | 7.61 Million CNY | 11.56% |
| 2003 Q2 | 8.88 Million CNY | 16.68% |
| 2003 Q3 | 4.1 Million CNY | -53.79% |
| 2002 Q3 | 5.86 Million CNY | 23.34% |
| 2002 FY | 28.19 Million CNY | -23.58% |
| 2002 Q1 | 10.74 Million CNY | 0.0% |
| 2002 Q2 | 4.75 Million CNY | -55.75% |
| 2002 Q4 | 6.82 Million CNY | 16.4% |
| 2001 FY | 36.89 Million CNY | -23.96% |
| 2000 FY | 48.52 Million CNY | -34.44% |
| 1999 FY | 74.01 Million CNY | 24.58% |
| 1998 FY | 59.41 Million CNY | 55.91% |
| 1997 FY | 38.1 Million CNY | 26.09% |
| 1996 FY | 30.22 Million CNY | 75.13% |
| 1995 FY | 17.25 Million CNY | 26.24% |
| 1994 FY | 13.67 Million CNY | 65.44% |
| 1993 FY | 8.26 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Jiangsu Hengrui Medicine Co., Ltd. | 4.3 Billion CNY | 86.57% |
| Zhangzhou Pientzehuang Pharmaceutical., Ltd | 2.79 Billion CNY | 79.344% |
| Zhejiang CONBA Pharmaceutical Co.,Ltd. | 591.57 Million CNY | 2.324% |
| Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. | 57 Million CNY | -913.717% |
| Aurora Optoelectronics Co.,Ltd. | -675.27 Million CNY | 185.569% |
| Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd | -38.27 Million CNY | 1609.663% |
| GuangYuYuan Chinese Herbal Medicine Co., Ltd. | 90.07 Million CNY | -541.469% |
| Tonghua Dongbao Pharmaceutical Co., Ltd. | 1.16 Billion CNY | 50.522% |